Literature DB >> 2337267

Characterization of an attenuated strain of Actinobacillus pleuropneumoniae, serotype 1.

S Rosendal1, J I MacInnes.   

Abstract

Pleuropneumonia is an important disease of swine caused by Actinobacillus pleuropneumoniae. Putative virulence determinants include capsule, lipopolysaccharide, and cytotoxin. We studied the virulence and virulence determinants of 2 strains: CM5 and CM5A of serotype 1. Strain CM5 was isolated from a pig with pleuropneumonia and passaged once in vitro; strain CM5A was a substrain of CM5 passaged 70 times in vitro. Pigs challenge exposed to an aerosol of 1.3 x 10(7) colony-forming units of CM5/ml died within 30 hours; pigs challenge exposed to an aerosol of 1.6 x 10(8) colony-forming units of CM5A/ml survived. The average thickness of the capsular layer was 137 nm in strain CM5 and 53 nm in strain CM5A in bacteria treated with homologous antibody and examined by transmission electron microscopy. Similarly, capsular material binding polycationic ferritin was found in colonies of strain CM5, but not in strain CM5A. The ratio of hexosamine to protein in extracted capsule of CM5 was more than twice that of CM5A. The polyacrylamide gel electrophoretic profile of the lipopolysaccharide, outer membrane proteins, and whole cell proteins did not differ between the 2 strains. Also, the amount of cytotoxin or endotoxin produced by the 2 strains during the logarithmic growth phase was not different. The electrophoretic profile of restriction endonuclease digested DNA was similar, with the exception of bands in the 750- and 620-basepair regions. It was concluded that attenuation of strain CM5A during in vitro passage was a result of reduced capsule production and that encapsulation is an important virulence determinant of A pleuropneumoniae, serotype 1.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2337267

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  8 in total

1.  Urease activity may contribute to the ability of Actinobacillus pleuropneumoniae to establish infection.

Authors:  J T Bossé; J I MacInnes
Journal:  Can J Vet Res       Date:  2000-07       Impact factor: 1.310

2.  Humoral antibody response and protective immunity in swine following immunization with the 104-kilodalton hemolysin of Actinobacillus pleuropneumoniae.

Authors:  J Devenish; S Rosendal; J T Bossé
Journal:  Infect Immun       Date:  1990-12       Impact factor: 3.441

3.  Transposon mutagenesis in Actinobacillus pleuropneumoniae with a Tn10 derivative.

Authors:  R I Tascon; E F Rodriguez-Ferri; C B Gutierrez-Martin; I Rodriguez-Barbosa; P Berche; J A Vazquez-Boland
Journal:  J Bacteriol       Date:  1993-09       Impact factor: 3.490

4.  Safety, stability, and efficacy of noncapsulated mutants of Actinobacillus pleuropneumoniae for use in live vaccines.

Authors:  T J Inzana; J Todd; H P Veit
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

5.  Association of Actinobacillus pleuropneumoniae capsular polysaccharide with virulence in pigs.

Authors:  Aloka B Bandara; Mark L Lawrence; Hugo P Veit; Thomas J Inzana
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

6.  Protective local and systemic antibody responses of swine exposed to an aerosol of Actinobacillus pleuropneumoniae serotype 1.

Authors:  J T Bossé; R P Johnson; M Nemec; S Rosendal
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

7.  Cloning and mutagenesis of a serotype-specific DNA region involved in encapsulation and virulence of Actinobacillus pleuropneumoniae serotype 5a: concomitant expression of serotype 5a and 1 capsular polysaccharides in recombinant A. pleuropneumoniae serotype 1.

Authors:  C K Ward; M L Lawrence; H P Veit; T J Inzana
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

8.  Microarray-based comparative genomic profiling of reference strains and selected Canadian field isolates of Actinobacillus pleuropneumoniae.

Authors:  Julien Gouré; Wendy A Findlay; Vincent Deslandes; Anne Bouevitch; Simon J Foote; Janet I MacInnes; James W Coulton; John H E Nash; Mario Jacques
Journal:  BMC Genomics       Date:  2009-02-24       Impact factor: 3.969

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.